Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Diabetes Care

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.23.11.1605PMID 11092281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.

  2000cited by this paper
• Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials

  2000cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• Rosiglitazone

  1999cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Troglitazone: an antidiabetic agent.

  1998cited by this paper
• Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

  1998cited by this paper
• Epidemiologic aspects of lipid abnormalities.

  1998cited by this paper
• Mechanisms and clinical effects of thiazolidinediones.

  1997cited by this paper
• Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.

  1997cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents.

  1995cited by this paper
• Differentiating Glucose Toxicity From Glucose Desensitization: A New Message From the Insulin Gene

  1994cited by this paper
• Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressure, in Obese, Insulin-Resistant Rhesus Monkeys

  1994cited by this paper
• Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.

  1990cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Convergent Metabolic Pathways in MASH Therapeutics: An AMPK‐Centric Analysis

  2026cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.

  2025cites this paper
• Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline.

  2025cites this paper
• Efficacy and safety of insulin sensitisers for treating type 2 diabetes: a network meta-analysis

  2025cites this paper
• Low dose pioglitazone (7.5 mg) provides efficacious glycemic control in Asian Indian patients with poorly controlled diabetes compared to 15 mg: A pilot randomized controlled parallel-group open-label trial over 12 months.

  2025cites this paper
• Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.

  2025cites this paper
• Unveiling Pharmacokinetics and Drug Interaction of Linagliptin and Pioglitazone HCl in Rat Plasma Using LC-MS/MS.

  2024cites this paper
• "Evaluation of the effects of pioglitazone on perivascular adipose tissue function, properties and structure in a rat model of type-2 diabetes."

  2024cites this paper
• Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-Controlled Study.

  2024cites this paper
• Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies

  2024cites this paper
• Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension.

  2023cites this paper
• Gentianella turkestanorum (Gand.) Holub, a Chinese Herbal Medicine that can Alleviate T2DM in Db/db Mice, and its Active Mechanism of Action

  2023cites this paper
• Metallothionein–Kidney Bean Polyphenol Complexes Showed Antidiabetic Activity in Type 2 Diabetic Rats by Improving Insulin Resistance and Regulating Gut Microbiota

  2023cites this paper
• A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells

  2023cites this paper
• Advances in the treatment of hepatogenous diabetes: A review

  2023cites this paper
• [Rediscovery of pioglitazone].

  2023cites this paper
• Predictors of Poor Glycemic Control and Increased Glucose Variability Among Admitted Moderate to Critical COVID-19 Patients with Type 2 Diabetes Mellitus: A Single Center Cross-sectional Study

  2023cites this paper
• HDL abnormalities in type 2 diabetes: Clinical implications.

  2023cites this paper
• Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease

  2023cites this paper
• Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1).

  2023cites this paper
• Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis

  2022cites this paper
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Downregulates the Inflammatory Response in Cutaneous Leishmaniasis Patients Without Interfering in Leishmania braziliensis Killing by Monocytes

  2022cites this paper
• Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review

  2022cites this paper
• Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance

  2022cites this paper
• Protective Effect Of Hydro-Ethanolic Extract Of Bushweed Flueggea Virosa On Renal Damage In Streptozotocin-Induced Hyperglycemia In Rat

  2022cites this paper
• Rescue of a peroxisome proliferator activated receptor gamma gene network in muscle after growth of human breast tumour xenografts

  2022cites this paper
• Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

  2021cites this paper
• Development and validation of a sensitive LC-MS/MS method for pioglitazone: application towards pharmacokinetic and tissue distribution study in rats

  2021cites this paper
• PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy

  2021cites this paper
• Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG.

  2021cites this paper
• An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes

  2021cites this paper
• Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway.

  2021cites this paper
• Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans

  2021cites this paper
• Thiazolidinediones (TZDs)

  2021cites this paper
• Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.

  2021cites this paper
• Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences.

  2021cites this paper
• The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans

  2021cites this paper
• Role of Perivascular Adipose Tissue-Derived Adiponectin in Vascular Homeostasis

  2021cites this paper
• Diabetes Mellitus

  2021cites this paper
• Chiglitazar: a novel pan-PPAR agonist.

  2021cites this paper
• Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease.

  2020cites this paper
• Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

  2020cites this paper
• A meta-analysis of randomized controlled trials

  2020cites this paper
• The efficacy and safety of pioglitazone in psoriasis vulgaris

  2020cites this paper
• Prevalence and factors associated with overweight and obesity among patients with type 2 diabetes mellitus in Uganda—a descriptive retrospective study

  2020cites this paper
• Hepatic Mitochondrial Remodeling is Mechanistically Linked to Insulin Resistance in Nonalcoholic Fatty Liver Disease

  2020cites this paper
• Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG

  2020cites this paper
• Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa

  2020cites this paper
• A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.

  2020cites this paper
• Reducing the burden of diabetes treatment: A review of low-cost oral hypoglycemic medications.

  2020cites this paper
• Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol

  2020cites this paper
• The Glycemic, Cardiovascular and Hepatic Outcomes of Pioglitazone Treatment: Evidence for Its Increased Use

  2020cites this paper
• Pioglitazone rescues mitochondrial lipid remodeling and pyruvate dehydrogenase hyperactivation in hepatic insulin resistance

  2020cites this paper
• RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Determination of Novel Promising Combination of Linagliptin and Pioglitazone HCl in Bulk and Laboratory Synthetic Mixture by Earth-Friendly Three Spectrophotometric Methods

  2020cites this paper
• Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment

  2019cites this paper
• Sitagliptin monoterapisi ile kombinasyon tedavilerinin karşılaştırılması

  2019cites this paper
• Medications for the Treatment of Type II Diabetes

  2019cites this paper
• A Model‐Based Meta‐Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses

  2019cites this paper
• From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

  2019cites this paper
• Conversion rate of prediabetes to diabetes in long-term followed patients

  2019cites this paper
• Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

  2019cites this paper
• Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas.

  2019cites this paper
• Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential

  2018cites this paper
• Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

  2018cites this paper
• The Role of Diabetes Care and Its Contributions to the Field of Diabetes: A Profile in Progress

  2018cites this paper
• Pharmacotherapy of type 2 diabetes: An update.

  2018cites this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial

  2018cites this paper
• Systems biology of Metabolic Syndrome development and treatment

  2018cites this paper
• Searching for novel PET radiotracers: imaging cardiac perfusion, metabolism and inflammation.

  2018cites this paper
• Effect of Hexadecyl Azelaoyl Phosphatidylcholine on Cardiomyocyte Apoptosis in Myocardial Ischemia-Reperfusion Injury: A Hypothesis

  2018cites this paper
• The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development

  2018cites this paper
• SAFETY AND EFFICACY OF PIOGLITAZONE AMONG TYPE 2 DIABETES MELLITUS PATIENTS RECEIVING LONG TERM HEMODIALYSIS

  2018cites this paper
• Can a multiple ascending dose study serve as an informative proof‐of‐concept study?

  2018cites this paper
• Dietary Apostichopus japonicus Alleviates Diabetes Symptoms and Modulates Genes Expression in Kidney Tissues of db/db Mice.

  2018cites this paper
• Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes

  2018cites this paper
• Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?

  2017cites this paper
• Clinical audit for the adherence to safety monitoring for pioglitazone use in patients with type 2 diabetes in the Al-Wazarat primary care center, Saudi Arabia

  2017cites this paper
• Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.

  2017cites this paper
• Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

  2017cites this paper
• Oral Antihyperglycemic Therapy for Type 2 Diabetes

  2017cites this paper
• Complications des maladies métaboliques et nouvelles approches thérapeutiques : développement d'outils pour des études de suivi longitudinal en imagerie nucléaire

  2017cites this paper
• Effect of Aloe vera on glycemic outcomes in patients with diabetes mellitus: a systematic review protocol.

  2017cites this paper
• Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction

  2017cites this paper
• Favorable cardiovascular effects of pioglitazone: a meta-analysis

  2017cites this paper
• Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

  2017cites this paper
• Effects of high fructose intake on the development of hypertension in the spontaneously hypertensive rats: the role of AT1R/gp91PHOX signaling in the rostral ventrolateral medulla.

  2017cites this paper
• Resolving the KgA1c paradox in the management of type 2 diabetes mellitus.

  2017cites this paper
• Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?

  2017cites this paper
• Retrospective analysis of primary and sequential care of type 2 diabetes patients in Taiwan

  2017cites this paper
• Hexane extract of raw ginger enhances adipocyte differentiation through its PPARγ ligand activity on 3T3-L1 preadipocytes

  2017cites this paper
• Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure

  2017cites this paper
• Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.

  2016cites this paper
• Dapagliflozin combination therapy in type 2 diabetes mellitus

  2016cites this paper
• Pharmacodynamic Effects of Low‐Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus

  2016cites this paper
• Obesity Context of Type 2 Diabetes and Medication Perspectives

  2016cites this paper
• Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor

  2016cites this paper
• The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study

  2016cites this paper
• The Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled Trial

  2016cites this paper